COLLEGE STATION, TX / ACCESSWIRE / November 19, 2020 / Strategic Vaccines, LLC today announced that Lockheed Martin will conduct a computational study of the Strategic Vaccines' proprietary manufacturing systems designed to address emerging viral threats, beginning with COVID-19.
These proprietary Test and Go Rapid Deployment (TANGO-RDP) manufacturing systems will be housed at the Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) at College Station.
"Strategic Vaccines is manufacturing FLOVID-20, an inhaled treatment for COVID-19 designed to keep patients out of the hospital," said Reid Rubsamen, M.D., CEO, Strategic Vaccines, LLC. "The TANGO-RDP manufacturing systems we'll establish at the Texas A&M CIADM site will enable us to quickly address emerging viral threats. Lockheed Martin has a unique skill set matching our requirements and is helping us with that process."
The FLOVID-20 therapeutic is stable at room temperature and designed for delivery by inhalation to patients with a positive COVID-19 test. Strategic Vaccines, LLC is manufacturing FLOVID-20 at it's partner company Oakwood Laboratories in Solon, Ohio, and expects to begin clinical trials next year.
"Lockheed Martin's work with Strategic Vaccines at Texas A&M is a great opportunity to apply our technical resources and experience to help defeat the COVID-19 threat," said Michele Evans, Executive Vice President of Lockheed Martin Aeronautics. "This exemplifies one of our core values - ‘Do What's Right' - by using our unique aerospace expertise to serve a global need."
"The Texas A&M System is tirelessly working to respond to this deadly pandemic," said John Sharp,Chancellor of The Texas A&M University System. "We welcome Strategic Vaccines new teammate Lockheed Martin into our Texas A&M CIADM ecosystem."
About Strategic Vaccines
Strategic Vaccines, LLC is a Public Private Partnership ("PPP") including San Francisco Bay Area Biotech Flow Pharma, Inc. defense contractor M7TecGroup, Texas A&M University and Solon, Ohio based Oakwood Laboratories, LLC.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 110,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
About the Texas A&M Center for Innovation in Advanced Development and Manufacturing
The Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) is founded on an initial $285.6 million public-private partnership with the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA). The public/private partnership includes an initial investment of $176.6 million from the U.S. government with the remainder cost-shared by commercial and academic partners as well as the State of Texas Emerging Technology Fund. The Center for Innovation was awarded to the Texas A&M University System in June 2012 and is part of a national strategy recommended in the August 2010 Public Health Emergency Medical Countermeasures Enterprise Review.
As one of three centers established as public-private partnerships with the U.S. Department of Health and Human Services to develop and manufacture countermeasures, the Texas A&M Center for Innovation will respond to the need for rapid and flexible manufacturing to bolster the nation's ability to respond to any attack or threat, including novel, previously unrecognized, naturally occurring emerging infectious diseases, as well as various chemical, biological, radiological and nuclear threats.
It is designed to facilitate rapid research and development (R&D), promote novel product development through both public and private partnerships, ensure domestic manufacturing surge capacity, assist in FDA approval of products, as well as mentor the next generation of public health professionals through workforce training and outreach. The center will not only enhance the nation's ability to produce life-saving countermeasures quickly and nimbly, it will also transition processes and technologies that will broadly impact both national and global public health.
The Center is part of the Public Health Preparedness and Response initiative that has been established at the Texas A&M Health Science Center (TAMHSC).
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. ("the Company"), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
Media Contact:
Strategic Vaccines, LLC
1041 Rellis Parkway, Suite 2312
College Station, Texas 77807
SOURCE: Strategic Vaccines, LLC